Skip to main content
Equibles
IOVA logo

IOVA

Iovance Biotherapeutics, Inc.
$3.93 -0.11 (-2.72%) At close · Jul 14
Market Cap
$1.75B
Shares
446,502,396

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.93 Open$4.07 Day$3.90–4.07 52W$1.70–5.63 Avg vol 30d13.4M Short int100.5M · 22.5% float · 7.1d Short vol63% Last earningsMay 7, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 7
Up next
Next earnings call
Aug 6, 2026 Est · unconfirmed · in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 7, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Equibles Rating blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 16.5 · calm Equity put/call 0.62
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg +26%
      above
      Price vs 50-day avg −1%
      below
      RSI (14) 45
      neutral
      MACD trend Negative
      52-week position 57%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Strong
      1-month return −4%
      trailing
      6-month return +61%
      trailing
      YTD return +44%
      this year
      Relative strength +50%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $4 › 200d $3 — 50d above 200d
      Institutional flow Accumulating
      10 of 288 funds reported for Jun 30 · net +465.1K sh shares
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      22.51% of float · ▼ -2.9% MoM · 7.1 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      288 holders — mid 3-yr range
      Squeeze score 80
      high risk · 0–100
      Fundamentals
      Strong
      EPS growth +15%
      Y/Y
      Free cash flow $-336.2M
      Balance sheet $163.1M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 101%
      annualized · 1-yr
      Max drawdown −54%
      past year
      ATR 7.8%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record
      Latest guidance · from the 8-K filed May 7, 2026
      2Q26
      Total product revenue Raised $86M – $88M
      prior qtr $71.43M midpoint +21.8% QoQ
      FY26
      Total product revenue Maintained $350M – $370M
      prior FY $263.5M midpoint +36.6% Y/Y

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      1 · 5 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +26% Bullish
      Price vs 50-day avg
      −1% Neutral
      RSI (14)
      45 Neutral
      MACD trend
      Negative Bearish
      52-week position
      57% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $4 › 200d $3 — 50d above 200d
      Institutional flow Accumulating
      10 of 288 funds reported for Jun 30 · net +465.1K sh shares
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      22.51% of float · ▼ -2.9% MoM · 7.1 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      288 holders — mid 3-yr range
      Price context
      position in its 52-week range
      52-wk low $2 Now $4 · 57% 52-wk high $6
      vs 200-day avg +26% vs 50-day avg -1%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      Gross margin from cost of sales 50% Q4 2025 —
      Manufacturing turnaround time 32 Q4 2025 —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      IOVA
      Iovance Biotherapeutics, Inc.
      this stock
      		$1.75B +44.0% +0.0% — 22.5%
      ONC
      BeOne Medicines Ltd.
      		 $439.30B +0.0% +22179.2% 894.0 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $120.89B +5.1% +46.2% 28.3 1.9%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $68.79B -14.9% +20.8% 16.0 3.3%
      ARGX
      Argenx SE
      		 $53.77B +2.2% — — 2.3%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      287
      % held
      59.2%
      Reported
      10 of 288
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      173
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      100.5M
      Days to cover
      7.1d
      Change
      -3.0M sh
      View
      Short Volume
      Short vol %
      63%
      As of
      Jul 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      1.6K
      Value
      $6.3K
      As of
      Jun 12, 2026
      View
      Off-Exchange
      Off-exchange %
      62.6%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $263.5M
      Net income (FY)
      $-391.0M
      EPS diluted
      $-1.09
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 2, 2026
      This year
      11
      View
      Proposed Sales
      Value
      $503.1K
      Shares
      50.0K
      Filed
      Nov 12, 2024
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jun 4, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      IOVA -9.7% -3.7% +61.1% -5.5% +44.0%
      SPY +0.6% +1.4% +11.0% +0.7% +10.3%
      vs SPY -10.2% -5.0% +50.1% -6.2% +33.7%
      Key facts CIK 1425205 CUSIP 462260100 13F (30d) 11 filings 10 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)